About Shouyao Holdings Company

The company was founded on April 19, 2016, and focuses on the development and production of innovative drugs with independent intellectual property rights. Currently, it has obtained 18 national clinical approvals for Class 1 innovative drugs. Among them, 1 new drug has been declared for marketing, 1 new drug has completed clinical phase III, 5 new drugs have entered clinical phase II, and 10 new drugs have entered clinical phase I. Let us forge Shouyao Holdings into an international pharmaceutical enterprise integrating R&D, production, and sales within a mechanism where “responsibilities, rights, and benefits” are clear and can be carried. The company is committed to developing new domestically produced targeted drugs with better curative effects and lower side effects to address unmet medical needs in the treatment of key tumor indications such as non-small cell lung cancer, lymphoma, hepatocellular cancer, pancreatic cancer, thyroid cancer, ovarian cancer, and leukemia. The company's main products are SY-4798, SY-5933, SY-4835, SY-5007, SY-707, SY-1530, and SY-3505. Corporate honors: In December 2021, the “2021 China Pharmaceutical Entrepreneurs, Scientists and Investors Conference” hosted by the China Pharmaceutical Enterprise Management Association and others announced the “2021 Top 100 Innovative Chinese Pharmaceutical Enterprises”, and First Pharmaceutical Holdings was on the list. The companies on the list represent the first faction of China's pharmaceutical innovation capabilities; in December 2020, Shoupharmaceutical Holdings was selected as the “2020 Zhongguancun International Frontier Science and Technology Innovation Competition” TOP10 in the biomedical field; it was recognized as a “Beijing G20 Innovation Leading Enterprise” by the Beijing Municipal Science and Technology Commission, etc.